Literature DB >> 20070504

Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.

C Treloar1, J Newland, J Rance, M Hopwood.   

Abstract

Uptake of treatment for hepatitis C virus (HCV) infection is very low particularly among people who have injected drugs. Opiate substitution treatment (OST) programs, with a high prevalence of people living with HCV, have been a site of growing interest in the delivery of hepatitis C treatment. There has been no exploration of OST clients' and health professionals' perceptions of the barriers and facilitators to uptake and delivery of HCV treatment in OST clinics from personal and organizational perspectives. This qualitative study involved interviews with 27 OST clients in New South Wales and a focus group and interviews with 22 Australian OST health professionals. Clients and health professionals viewed hepatitis C treatment in OST as a 'one-stop-shop' model which could increase access to and uptake of treatment and build on existing relationships of trust between OST client and health professional. Elements of the organizational culture were also noted as barriers to HCV treatment delivery including concerns about confidentiality, lack of discussion of HCV treatment and that HCV treatment was not perceived by clinicians as a legitimate activity of OST clinics. OST client participants also reported a number of personal barriers to engaging with HCV treatment including family responsibilities (and concerns about treatment side effects), unstable housing, comorbidities and perceptions of the unsatisfactory level of treatment efficacy. These findings emphasize the need for future research and delivery of services which addresses the complexity of care and treatment for people in marginalized social circumstances.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20070504     DOI: 10.1111/j.1365-2893.2009.01250.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  42 in total

1.  Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment.

Authors:  Andrew H Talal; Rositsa B Dimova; Randy Seewald; Raymond H Peterson; Marija Zeremski; David C Perlman; Don C Des Jarlais
Journal:  J Subst Abuse Treat       Date:  2012-03-08

2.  Strategies used by people who inject drugs to avoid stigma in healthcare settings.

Authors:  Dea L Biancarelli; Katie B Biello; Ellen Childs; M Drainoni; Peter Salhaney; Alberto Edeza; Matthew J Mimiaga; Richard Saitz; Angela R Bazzi
Journal:  Drug Alcohol Depend       Date:  2019-03-08       Impact factor: 4.492

3.  Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore.

Authors:  Oluwaseun Falade-Nwulia; Risha Irvin; Alana Merkow; Mark Sulkowski; Alexander Niculescu; Yngvild Olsen; Kenneth Stoller; David L Thomas; Carl Latkin; Shruti H Mehta
Journal:  J Subst Abuse Treat       Date:  2019-01-30

4.  The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.

Authors:  Sonya A MacParland; Marc Bilodeau; Jason Grebely; Julie Bruneau; Curtis Cooper; Marina Klein; Selena Sagan; Norma Choucha; Louise Balfour; Frank Bialystok; Mel Krajden; Jennifer Raven; Eve Roberts; Rodney Russell; Michael Houghton; D Lorne Tyrrell; Jordan J Feld
Journal:  Can J Gastroenterol Hepatol       Date:  2014-10

5.  Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis.

Authors:  Jason Grebely; Lucy Tran; Louisa Degenhardt; Alexander Dowell-Day; Thomas Santo; Sarah Larney; Matthew Hickman; Peter Vickerman; Clare French; Kerryn Butler; Daisy Gibbs; Heather Valerio; Phillip Read; Gregory J Dore; Behzad Hajarizadeh
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

6.  HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.

Authors:  Tessa M Nápoles; Abigail W Batchelder; Ada Lin; Lissa Moran; Mallory O Johnson; Martha Shumway; Anne F Luetkemeyer; Marion G Peters; Kellene V Eagen; Elise D Riley
Journal:  J Public Health (Oxf)       Date:  2019-12-20       Impact factor: 2.341

Review 7.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

8.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17

Review 9.  Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels.

Authors:  Jason Grebely; Megan Oser; Lynn E Taylor; Gregory J Dore
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

10.  Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response.

Authors:  Samali Lubega; Uchenna Agbim; Miranda Surjadi; Megan Mahoney; Mandana Khalili
Journal:  Liver Int       Date:  2013-03-20       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.